BIMO Carves Out Special Investigations Branch To Handle Inspection Tip-offs
This article was originally published in The Gray Sheet
Executive Summary
Creation of a CDRH Bioresearch Monitoring branch for special investigations will free up remaining staff to focus on "core" activities and meet Medical Device User Fee & Modernization Act timeframes, according to program officials
You may also be interested in...
“For Cause” Inspections Find Galloping Clinical Trial Violation Rate
The violation rate for clinical trial sponsors shot up in fiscal year 2007, hitting a 10-year high, with FDA finding many of the problems during inspections triggered by complaints, according to CDRH
“For Cause” Inspections Find Galloping Clinical Trial Violation Rate
The violation rate for clinical trial sponsors shot up in fiscal year 2007, hitting a 10-year high, with FDA finding many of the problems during inspections triggered by complaints, according to CDRH
Serious Clinical Trial Violations Down In FY 2005 – FDA’s Marcarelli
Device companies showed marked improvement in complying with FDA clinical trial regulations during the past year, according to FDA